Download biomedica product list
Customized Testing Solutions for ELISA, Luminex, and microRNA
Simplify Your Testing Process
We at Biomedica provide tailored analytical testing services for ELISA Kits, Luminex Assays, and microRNA Analysis.
Customized Testing Solutions for ELISA, Luminex, and microRNA
Features:
-Expert-Driven: All analyses conducted by experienced professionals
-High-Quality: Committed to delivering excellence in every test
-Flexible: Customized solutions designed to meet your specific requirements
-Efficient: Save time and resources with our quick turnaround times
Discover more about the Biomedica Service Measurements here
Our Testing Services Include:
ELISA Assay Kits
We provide services for our proprietary Biomedica ELISA kits (refer to our product list), as well as for ELISA assays from other suppliers.
Luminex Technology Multiplex Assays
We employ Luminex xMAP® (multiple analyte profiling) technology to perform immunoassays that allow for the concurrent detection and measurement of multiple biomarkers.
For additional details, please view our workflow chart or contact us (info@bmgrp.com) directly to discuss how we can assist with your specific research needs.
NEXT-GENERATION SEQUENCING & RT-qPCR MICRORNA SERVICES
We offer a comprehensive suite of high-quality RNA services, including RNA extraction, next-generation sequencing (NGS), RT-qPCR, and customized microRNA signature analysis, all carried out by our skilled laboratory team. Our services include:
- RNA extraction from biofluids (such as serum, plasma, extracellular vesicles), cells, and tissues, with quality control of total RNA using Bioanalyzer chips
- Next-generation sequencing (NGS)
- RT-qPCRCell-type specific microRNA and mRNA analysis within complex tissues, along with tailored microRNA signature analysis
For more information about our microRNA services, please visit our website or contact us directly (info@bmgrp.com).
Literature
Gyöngyösi M, Guthrie J, Hasimbegovic E, Han E, Riesenhuber M, Hamzaraj K, Bergler-Klein J, Traxler D, Emmert MY, Hackl M, Derdak S, Lukovic D. Critical analysis of descriptive microRNA data in the translational research on cardioprotection and cardiac repair: lost in the complexity of bioinformatics. Basic Res Cardiol. 2025 Jun;120(3):443-472. doi: 10.1007/s00395-025-01104-1. Epub 2025 Apr 9. PMID: 40205177; PMCID: PMC12159128.
Abstract
The unsuccessful translation of cardiac regeneration and cardioprotection from animal experiments to clinical applications in humans has raised the question of whether microRNA bioinformatics can narrow the gap between animal and human research outputs. We reviewed the literature for the period between 2000 and 2024 and found 178 microRNAs involved in cardioprotection and cardiac regeneration. On analyzing the orthologs and annotations, as well as downstream regulation, we observed species-specific differences in the diverse regulation of the microRNAs and related genes and transcriptomes, the influence of the experimental setting on the microRNA-guided biological responses, and database-specific bioinformatics results. We concluded that, in addition to reducing the number of in vivo experiments, following the 3R animal experiment rules, the bioinformatics approach allows the prediction of several currently unknown interactions between pathways, coding and non-coding genes, proteins, and downstream regulatory elements. However, a comprehensive analysis of the miRNA-mRNA-protein networks needs a profound bioinformatics and mathematical education and training to appropriately design an experimental study, select the right bioinformatics tool with programming language skills and understand and display the bioinformatics output of the results to translate the research data into clinical practice. In addition, using in-silico approaches, a risk of deviating from the in vivo processes exists, with adverse consequences on the translational research.
Krammer TL, Mayr M, Hackl M. microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring. Int J Mol Sci. 2020 May 14;21(10):3477. doi: 10.3390/ijms21103477. PMID: 32423125; PMCID: PMC7278969.
Abstract
Given the high morbidity and mortality of cardiovascular diseases (CVDs), novel biomarkers for platelet reactivity are urgently needed. Ischemic events in CVDs are causally linked to platelets, small anucleate cells important for hemostasis. The major side-effect of antiplatelet therapy are life-threatening bleeding events. Current platelet function tests are not sufficient in guiding treatment decisions. Platelets host a broad spectrum of microRNAs (miRNAs) and are a major source of cell-free miRNAs in the blood stream. Platelet-related miRNAs have been suggested as biomarkers of platelet activation and assessment of antiplatelet therapy responsiveness. Platelets release miRNAs upon activation, possibly leading to alterations of plasma miRNA levels in conjunction with CVD or inadequate platelet inhibition. Unlike current platelet function tests, which measure platelet activation ex vivo, signatures of platelet-related miRNAs potentially enable the assessment of in vivo platelet reactivity. Evidence suggests that some miRNAs are responsive to platelet inhibition, making them promising biomarker candidates. In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use of platelet-related miRNAs as biomarkers for CVD and antiplatelet therapy monitoring, but also highlight remaining gaps in our knowledge and uncertainties regarding clinical utility. We also elaborate on technical issues and limitations concerning plasma miRNA quantification.